Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.43 |
| ▸ | GCK | P35557 | 2/20 | 0.42 |
| ▸ | GCKR | Q14397 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10202995 | 0.85 | PIK3CD (0.48) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL20985293 | 0.84 | NOS3 (0.48) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL13483886 | 0.83 | PIK3CD (0.52) | NOS3NOS2KDM4EHSD17B10DGAT1 | |
| SCHEMBL27451941 | 0.82 | NOS3 (0.46) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL30256450 | 0.82 | GCK (0.47) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL30940494 | 0.82 | GCK (0.47) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL1725656 | 0.82 | GCK (0.47) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL16885530 | 0.82 | GCK (0.47) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL18745835 | 0.79 | NPC1 (0.46) | NOS3NOS2KDM4EHSD17B10ALOX5AP | |
| SCHEMBL23763700 | 0.77 | KDM4E (0.36) | NOS3NOS2KDM4EHSD17B10ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727647-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103465-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4615839-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| CN-120152973-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114466839-B | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024259178-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| EP-1742935-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1740155-A1 | POLYCYLIC THIAZOLES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1737852-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005121126-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005099673-A1 | POLYCYLIC THIAZOLES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005099711-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005100349-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | NOS3 4682/4885NOS2 4718/4885KDM4E 1336/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | NOS3 1297/4885NOS2 1908/4885KDM4E 3666/4885 |
| US-20050227989-A1 | Polycyclic thiazoles as potassium ion channel modulators | KCNJ2, KCNA3, KCNN3 | NOS3 4682/4885NOS2 4743/4885KDM4E 1920/4885 |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | NOS3 4494/4885NOS2 4498/4885KDM4E 1618/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | NOS3 4052/4885NOS2 4229/4885KDM4E 2050/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | NOS3 2875/4885NOS2 2072/4885KDM4E 1189/4885 |
| US-20260103465-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | GSK3A, GSK3B, GYS2 | NOS3 1200/4885NOS2 3004/4885KDM4E 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.